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ABSTRACT
This retrospective study investigated the clinical signiﬁcance and impact of Stenotrophomonas maltophilia
bacteraemia in 49 haematology and oncology patients at a tertiary referral medical centre in Taipei
between July 1999 and December 2003. Sixteen patients had 24 episodes of central venous catheter
(CVC)-related bacteraemia, with the main clinical characteristics being a nosocomial bacteraemia
(100%), preceding antibiotic therapy (94%), bacteraemia developed in a general ward (87%),
immunosuppressive therapy (75%), in-situ CVC-related bacteraemia (75%), and neutropenia (63%).
Only four (25%) patients had inﬂammatory signs at the CVC site following diagnosis of bacteraemia.
Five patients had recurrent bacteraemia, with risk-factors being long-lasting (>10 days) neutropenia
(p 0.036) and an initial failure to remove the CVC (p 0.001). These cases did not involve re-infection, as
the same S. maltophilia strain was identiﬁed following random ampliﬁed polymorphic DNA (RAPD)
analysis of the initial and subsequent isolates. However, relapses could occur after long latency periods
(maximum, 200 days). Most patients were cured after removal of the CVC, even without appropriate
antibiotic treatment. Physicians should have a high index of suspicion for CVC-related bacteraemia with
haematology and oncology patients with CVCs and S. maltophilia bacteraemia. In addition to
appropriate antibiotic therapy, removal of the CVC is crucial for successful treatment of CVC-related
S. maltophilia bacteraemia and prevention of relapses.
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INTRODUCTION
Central venous catheters (CVCs) are used
widely for serial chemotherapy, repeated blood
transfusions, parenteral nutrition, and bone
marrow or peripheral blood stem-cell transplan-
tation in haematology and oncology patients. As
a consequence, CVC-related infection is encoun-
tered increasingly. The epidemiological pattern
of pathogens has changed during the past two
decades, and the incidence of CVC-related
Gram-negative bacteraemia has increased [1–3].
In particular, CVCs are the most common
source of non-fermentative Gram-negative bac-
teraemia, with Stenotrophomonas maltophilia being
one of the organisms isolated most commonly
[3–6]. S. maltophilia (formerly Xanthomonas malto-
philia) was ﬁrst isolated by Hugh in 1958 [7,8]
and has recently emerged as a nosocomial
pathogen with multidrug resistance, including
to carbapenems [9,10]. Many studies have report-
ed that indwelling CVCs are not only a
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predisposing factor for acquiring S. maltophilia
bacteraemia, but are also one of the most
common origins of the bacteraemia [11–17].
Thus, investigation of CVC-related S. maltophilia
bacteraemia is an important clinical issue. The
aim of the present study was to analyse the
clinical signiﬁcance and impact of CVC-related
S. maltophilia bacteraemia in haematology and
oncology patients.
PATIENTS AND METHODS
Patient identiﬁcation
Patients with S. maltophilia bacteraemia were identiﬁed retro-
spectively from blood culture reports of the clinical microbio-
logy laboratory at Taipei Veterans General Hospital between
July 1999 and December 2003. Taipei Veterans General
Hospital is a medical centre and teaching hospital with
c. 2900 beds in northern Taiwan. The medical charts of the
patients were reviewed and those with underlying haemato-
logical or oncological disease, whose diagnoses fulﬁlled the
deﬁnition of CVC-related bacteraemia, were analysed to
determine demographical information, clinical conditions
and laboratory data, antimicrobial susceptibility of isolates,
clinical treatments and outcomes.
Deﬁnitions
An episode of signiﬁcant bacteraemia was deﬁned as one or
more blood cultures positive for S. maltophilia, together with
clinical symptoms or signs of systemic or local infection.
Bacteraemia without symptoms or signs of infection was
considered to be contamination and was excluded. Multiple
episodes of bacteraemia developing within 1 week in the
same patient, or no clinical defervescence from a previous
episode, were considered to be a single episode, and the data
for the ﬁrst episode were used in the analysis. CVC-related
bacteraemia was recorded when S. maltophilia was isolated
simultaneously from blood and either the tip of the catheter
or purulent discharge from the CVC site, or there was a
positive blood culture for S. maltophilia with the presence of
inﬂammation at the CVC site without another identiﬁable
source of infection. CVCs included central venous pressure
catheters and in-situ CVCs (including Hickman catheters,
port-A catheters and permanent catheters). Nosocomial bac-
teraemia was deﬁned as bacteraemia occurring ‡48 h after
admission, or bacteraemia for which the patient had been
hospitalised at any time within the previous month. Pro-
longed hospitalisation was deﬁned as hospitalisation for
>2 weeks before bacteraemia was diagnosed. Shock was
deﬁned as a systolic blood pressure of <90 mm Hg or a need
for inotropic agents to maintain blood pressure. Previous
antibiotic therapy was deﬁned as administration of intrave-
nous antibiotics for >24 h within the 30-day period before
bacteraemia was diagnosed. Immunosuppressive therapy
included chemotherapy within 1 month before bacteraemia
occurred, or bone marrow transplantation. Neutropenia and
long-lasting neutropenia were deﬁned as an absolute neu-
trophil count <500 ⁄mm3 and a neutropenia duration of
>10 days, respectively. Thrombocytopenia was deﬁned as a
platelet count <100 000 mm3. Appropriate antibiotic therapy
was deﬁned as the use of at least one intravenous antibiotic to
which the microorganism was susceptible within 72 h of the
diagnosis of bacteraemia. Initial and ﬁnal removal of the CVC
indicated that the CVC was removed following the ﬁrst
episode of bacteraemia or ultimately, respectively. Bacterae-
mia-related mortality was deﬁned as death attributed to CVC-
related S. maltophilia bacteraemia, as judged from the clinical
course, response to treatment, and severity of the underlying
disease.
Microbiology
Blood culture samples were processed using the BACTEC
NR-660 instrument (Becton Dickinson, Sparks, MD, USA).
All positive cultures were examined following Gram’s stain
and were subcultured on blood agar plates and eosin–
methylene blue agar plates for further identiﬁcation. The
ID32 GN system (bioMe´rieux, Marcy l’Etoile, France) was
used for identifying S. maltophilia. All blood culture isolates
were stored at )70C. The BD Phoenix Automated Micro-
biology System (Becton Dickinson, Pont de Claix, France)
with panel NMIC ⁄ ID-24 was used to conﬁrm bacterial
identiﬁcations and for determination of MICs.
Random ampliﬁed polymorphic DNA (RAPD) analysis
Primers 270, 5¢-TGCGCGCGGG, and 272, 5¢-AGCGGGCCAA,
were used for RAPD analysis of the S. maltophilia isolates as
described previously [18].
Statistical analysis
Categorical variables were analysed using the chi-square or
Fisher’s exact test, as appropriate. Multivariate analysis was
performed by logistic regression. All p values were two-tailed,
with p <0.05 considered to be statistically signiﬁcant.
RESULTS
Between July 1999 and December 2003, 49
patients with underlying haematological or onc-
ological disease were diagnosed with S. malto-
philia bacteraemia. Of these, 42 had CVCs at the
time of diagnosis of bacteraemia, and 16 patients
were identiﬁed subsequently as having 24 epi-
sodes of CVC-related bacteraemia. Five patients
had recurrent bacteraemia (two patients with two
episodes each; three patients with three episodes
each).
The patients’ clinical characteristics and
demographical data are listed in Table 1, and
Table 2 lists the risk-factors for recurrent bac-
teraemia. Long-lasting neutropenia (p 0.036) and
failure to remove the CVC following the initial
diagnosis of bacteraemia (p 0.001) were statisti-
cally signiﬁcant risk-factors for recurrent bacter-
aemia in the univariate analysis. However, no
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signiﬁcant difference was found between the
two groups in the multivariate analysis (data
not shown).
The clinical characteristics of the ﬁve patients
with recurrent bacteraemia are summarised in
Table 3 (cases 1–5). Patients 1 and 2 had two
episodes each (i and ii) and patients 3–5 had three
episodes each (i, ii and iii). No inﬂammatory signs
were observed at the CVC site following the
initial episode of bacteraemia in any of these
patients. All CVCs were in situ (four port-A
catheters and one Hickman catheter). The median
period from CVC insertion to the ﬁrst episode of
bacteraemia was 33 (range 19–127) days. The
RAPD-PCR proﬁles of the 13 isolates from the ﬁve
patients are shown in Fig. 1. Isolates from the
same patient were identical, with the exception of
patient 3, whose ﬁrst isolate was different from
the other two.
DISCUSSION
CVC-related infection is one of the major compli-
cations with haematology and oncology patients,
and usually requires removal of the infected CVC
to cure the infection [6,15,19]. Although several
risk-factors associated with CVC-related infection
have been identiﬁed [20], it is impossible to
prevent completely. During the last two decades,
the incidence of CVC-related Gram-negative bac-
teraemia [1–3] and septicaemia caused by
S. maltophilia have increased [15]. S. maltophilia,
as well as other non-fermentative Gram-negative
bacilli, may contaminate the infusate and enter
the catheter. Several properties of S. maltophilia,
including the presence of ﬂagella, ﬁmbriae and a
positive charge, make this organism prone to
adhesion to glass, Teﬂon and abiotic surfaces [21–
23], and suggest that this organism is capable of
adhering to and forming a bioﬁlm on medical
implants and catheters, resulting eventually in
infection. Thus, CVC-related S. maltophilia bacter-
aemia is an emerging and important infection
among haematology and oncology patients.
Nosocomial bacteraemia (100%), previous anti-
biotic therapy (94%), bacteraemia developed in a
general ward (87%), immunosuppressive therapy
Table 1. Clinical characteristics of central venous catheter-
related Stenotrophomonas maltophilia bacteraemia among
haematology and oncology patients
Characteristics
No. (%)
(n = 16)
Age, median (range), years 48.5 (6–78)
Gender
Female 9 (56)
Male 7 (44)
Underlying condition
Haematological disease 9 (56)
Solid tumour 7 (44)
Immunosuppressive therapy 12 (75)
Diabetes mellitus 3 (19)
Chronic liver disease 1 (6)
Clinical condition
Prolonged hospitalisation 8 (50)
Mechanical ventilation 3 (19)
Total parenteral nutrition 2 (13)
Shock 6 (38)
Neutropenia 10 (63)
Long-lasting neutropenia 6 (38)
Thrombocytopenia 9 (56)
Previous antibiotic therapy 15 (94)
CVC site inﬂammation 4 (25)
Bacteraemia
Days from admission to bacteraemia,
median (range)
8.5 (0–48)
Days from CVC insertion to ﬁrst episode
of bacteraemia, median (range)
47.5 (4–776)
Nosocomial bacteraemia 16 (100)
Hospital setting
Intensive care unit 2 (13)
General ward 14 (87)
CVC devices
CVP catheter-related 4 (25)
In-situ CVC-relateda 12 (75)
Polymicrobial 6 (38)
Treatment
Appropriate antibiotic therapy 3 (19)
Removal of CVCs, initially 10 (63)
Removal of CVCs, ultimately 13 (81)
Outcome
Bacteraemia-related mortality 3 (19)
CVC, central venous catheter; CVP, central venous pressure catheter.
aIn-situ CVC includes Hickman catheters, port-A catheters and permanent
catheters.
Table 2. Risk-factors for recurrent central venous catheter-
related Stenotrophomonas maltophilia bacteraemia
Risk-factor
Non-recurrent
bacteraemia
n (%)
(total n = 11)
Recurrent
bacteraemia
n (%)
(total n = 5) pa
Age, median (range), years 60 (21–78) 39 (6–75) 0.496
Gender, male ⁄ female 5 (45) ⁄ 6 (55) 4 (80) ⁄ 1 (20) 0.308
Clinical condition
Haematological disease 5 (45) 4 (80) 0.308
Immunosuppressive
therapy
7 (64) 5 (100) 0.245
Diabetes mellitus 3 (18) 1 (20) 1.000
Prolonged hospitalisation 5 (45) 3 (60) 1.000
Mechanical ventilation 2 (18) 1 (20) 1.000
Total parenteral nutrition 1 (9) 1 (20) 1.000
Shock 3 (17) 3 (60) 0.299
Long-lasting neutropenia 2 (18) 4 (80) 0.036
CVC site inﬂammation 4 (36) 0 (0) 0.245
Days from CVC insertion
to ﬁrst episode of
bacteraemia,
median (range)
64 (4–776) 33 (19–127) 0.533
Bacteraemia in ICU 2 (18) 0 (0) 1.000
In-situ CVC-related
bacteraemia
7 (64) 5 (100) 0.245
Polymicrobial 5 (45) 1 (20) 0.588
Treatment
Inappropriate antibiotic
therapy
9 (82) 4 (80) 1.000
Removal of CVCs, initially 10 (91) 0 (0) 0.001
aDifference between non-recurrent and recurrent cases of bacteraemia by univariate
analysis.
CVC, central venous catheter; ICU, intensive care unit.
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(75%), in-situ CVC-related bacteraemia (75%)
and neutropenia (63%) were the main clinical
characteristics associated with CVC-related
S. maltophilia bacteraemia of haematology and
oncology patients. All of the patients in the
present study had nosocomial infections, and
most (15 patients, 94%) had received previous
antibiotic therapy, as had patients in previous
studies of S. maltophilia bacteraemia [11–14,24].
However, 87% of cases of bacteraemia developed
in the general ward rather than in the intensive
care unit, which is often the source of drug-
resistant bacteria. Although increasing numbers
of S. maltophilia infections are found in patients
who have been treated with imipenem, to which
the organism is intrinsically resistant [25], only
three (20%) of 15 patients in the present study
had received imipenem. The wide-ranging inter-
val (4–776 days) between CVC insertion and the
development of bacteraemia among the patients
indicated that both sterile insertion of the CVC
and long-term aseptic CVC care are important for
preventing CVC-related S. maltophilia bacterae-
mia. The latter aspect was also emphasised in
the study of Penzak et al. [26], especially for
patients providing their own CVC care.
Five (31%) of the 16 patients in the present
study had recurrent bacteraemia. The univariate
analysis identiﬁed failure to remove the CVC
once infection was suspected and long-lasting
neutropenia as signiﬁcant risk-factors (Table 2),
both of which have been reported previously
Table 3. Clinical characteristics of central venous catheter-related recurrent Stenotrophomonas maltophilia bacteraemia
Case
Age ⁄
gender
Underlying
disease Episode
CVC
site
inﬂammation
Duration from
CVC insertion
to bacteraemia
(days)
Long-lasting
neutropeniaa
Appropriate
antibiotic
Removal
of
CVC
Response to
treatment
1 6 ⁄M Anaplastic
oligodendroma
of brain
i
ii
N
N
127
186
Y
Y
N
N
N
Y
Improve
Cure
CVC type: Port-A
Port-A tip culture (+)
2 75 ⁄M Acute
lymphoblastic
leukaemia
i
ii
N
Y
19
217
N
N
Y
Y
N
N
Improve
Died
CVC type: Port-A
3 39 ⁄ F Aplastic anaemia,
diabetes mellitus
i
ii
N
N
23
274
Y
N
N
N
N
N
Improve
Improve
CVC type: Port-A iii N 361 Y Y Y Cure
Port-A tip culture (+)
4 50 ⁄M Large B-cell lymphoma i N 40 Y N N Improve
CVC type: Port-A ii N 54 Y N N Improve
Port-A tip culture (+) iii N 72 N N Y Cure
5 30 ⁄M Aplastic anaemia i N 33 Y N N Failure
CVC type: Hichman
catheter
ii
iii
N
Y
45
60
Y
Y
N
N
N
N
Failure
Died
aAbsolute neutrophil count <500 ⁄mm3 for >10 days.
CVC, central venous catheter; N, no; Y, yes; i, ﬁrst isolate; ii, second isolate; iii, third isolate.
A
M i ii
1 2 3 4 5
i ii i ii iii i ii iii i ii iii M
M i ii
1 2 3 4 5
i ii i ii iii i ii iii i ii iii M
B
Fig. 1. Random ampliﬁed polymorphic DNA (RAPD)
patterns of Stenotrophomonas maltophilia isolates from
patients 1–5 (Table 3). (A) With primer 270. (B) With
primer 272. The RAPD patterns of repeat isolates from
patients 1, 2, 4 and 5 are identical. For patient 3, the RAPD
pattern for the ﬁrst isolate is different from that for the
second and third isolates. M, DNA size markers; i, ﬁrst
isolate; ii, second isolate; iii, third isolate.
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[6,13,27]. However, no statistically signiﬁcant
associations were identiﬁed after multivariate
analysis, perhaps because of the small number
of patients analysed. The results of RAPD analysis
for the ﬁve patients with recurrent S. maltophilia
bacteraemia indicated that the recurrent bacter-
aemia was caused mostly by relapses rather than
by re-infection with different strains. This sug-
gests that the same strain of S. maltophilia could
colonise a CVC, without identiﬁable symptoms or
signs of infection between episodes, and thus
cause relapsing bacteraemia if the CVC is not
removed. For patient 2 (Table 3), the bacteraemia
reoccurred after a period of c. 200 days. Thus,
without removal of the CVC, a good response to
empirical antibiotic treatment does not necessar-
ily guarantee eradication of infection.
The possibility of CVC-related infection should
be considered seriously in haematology and
oncology patients with a CVC who acquire
S. maltophilia bacteraemia. However, diagnosis of
CVC-related infection is troublesome in such
patients because the inﬂammatory signs at the
CVC site may not be as prominent as in immuno-
competent hosts. In addition, the infected deposits
accumulate under the venous access port septum,
and intra-luminal catheter colonisation by the
microorganism may not cause overt cutaneous
inﬂammation at the CVC site [28]. In the study by
Huang et al. [3], a high proportion of venous port-
related Gram-negative bacteraemias were diag-
nosed without local inﬂammatory signs. Similarly,
only four (25%) of the 16 patients in the present
study had inﬂammatory signs at the CVC site
during the ﬁrst episode of bacteraemia (Table 1).
In the ﬁve patients with recurrent bacteraemia, no
obvious inﬂammationwas observed initially at the
CVC site, and fever subsided without removal of
the CVC or appropriate antibiotic therapy
(Table 3). Accordingly, CVC-related S. maltophilia
bacteraemia might easily be missed because of an
absence of clinical inﬂammatory signs at the CVC
site and a good response to antibiotic treatment
clinically. For haematology and oncology patients
with CVCs and S. maltophilia bacteraemia, it is
suggested that a high index of suspicion for CVC-
related bacteraemia should be maintained, despite
an absence of identiﬁable local inﬂammatory signs
at the CVC site. In cases where the CVC is
retained, quantitative blood cultures [29] or dif-
ferential time-to-positivity [30] may be helpful in
reaching a diagnosis.
Treatment of S. maltophilia infection is prob-
lematic because of this organism’s intrinsic broad-
spectrum resistance to antibiotics, including carb-
apenems, the unreliability of results with disk-
diffusion tests, and the debilitated status of many
infected patients [9]. In the present study, only
three (19%) patients received appropriate antibi-
otic treatment, although, because this was a
retrospective study, the susceptibility test results
comprised the MICs determined following re-
identiﬁcation of the bacteria, rather than the
original disk-diffusion results which formed the
initial basis for treatment. However, most of the
patients who received inappropriate antibiotic
treatment (12 of 13 patients, 92%) were cured and
survived after removal of the CVC. Three (19%)
deaths related to bacteraemia were identiﬁed;
removal of the CVC was either delayed or not
performed in these cases. One patient died
despite administration of appropriate antibiotics,
while the other two patients (2 and 5; Table 3)
died after the bacteraemia reoccurred. In contrast,
no deaths occurred among the 13 patients from
whom the CVC was removed, although only two
of these patients received appropriate antibiotic
therapy. In the univariate analysis, the mortality
rate among patients who had initial or ultimate
removal of the CVC was signiﬁcantly lower than
that among those without removal (0% vs. 50%,
p 0.036, and 0% vs. 100%, p 0.002, respectively).
Thus, removal of the CVC may be more important
than appropriate antibiotic therapy in the man-
agement of CVC-related S. maltophilia bacterae-
mia in haematology and oncology patients.
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